122 related articles for article (PubMed ID: 37321066)
1. R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed.
Chirban AM; Vega EA; Kutlu OC; Mellado S; Kozyreva O; Zauls AJ; Panettieri E; Salirrosas O; Freeman R; Conrad C
Surg Oncol; 2023 Aug; 49():101961. PubMed ID: 37321066
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence?
Parikh AA; Maiga A; Bentrem D; Squires MH; Kooby DA; Maithel SK; Weber SM; Cho CS; Katz M; Martin RC; Scoggins CR; Sutton J; Ahmad SA; Abbott DE; Carr J; Kim HJ; Yakoub D; Idrees K; Merchant N
J Am Coll Surg; 2016 Apr; 222(4):448-56. PubMed ID: 26895735
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy versus chemoradiation in high-risk pancreatic adenocarcinoma: A propensity score-matched analysis.
Raoof M; Blakely AM; Melstrom LG; Lee B; Warner SG; Chung V; Singh G; Chen YJ; Fong Y
Cancer Med; 2019 Oct; 8(13):5881-5890. PubMed ID: 31414566
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection.
Naffouje SA; Sabesan A; Kim DW; Carballido E; Frakes J; Hodul P; Denbo JW; Malafa M; Fleming J; Hoffe S
J Gastrointest Surg; 2022 Feb; 26(2):376-386. PubMed ID: 34506031
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Care and Outcomes of Adjuvant Chemoradiation for Node-Positive Pancreatic Adenocarcinoma.
Malakhov N; Lee A; Albert A; Lederman A; Byun J; Safdieh J; Schreiber D
J Gastrointest Cancer; 2020 Jun; 51(2):506-514. PubMed ID: 31236851
[TBL] [Abstract][Full Text] [Related]
6. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
8. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment.
Winer LK; Cortez AR; Ahmad SA; Wima K; Olowokure O; Latif T; Kharofa J; Patel SH
J Surg Res; 2021 Mar; 259():442-450. PubMed ID: 33059910
[TBL] [Abstract][Full Text] [Related]
11. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study.
Kamarajah SK; White SA; Naffouje SA; Salti GI; Dahdaleh F
Ann Surg Oncol; 2021 Oct; 28(11):6790-6802. PubMed ID: 33786676
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of additional therapy for residual pancreatic cancer.
Yamada S; Sonohara F; Tashiro M; Murotani K; Takami H; Hayashi M; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujii T; Kodera Y
Surg Today; 2020 May; 50(5):440-448. PubMed ID: 31650262
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma.
Mehtsun WT; McCleary NJ; Maduekwe UN; Wolpin BM; Schrag D; Wang J
JAMA Oncol; 2022 Jan; 8(1):88-95. PubMed ID: 34854874
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival.
Morganti AG; Cellini F; Buwenge M; Arcelli A; Alfieri S; Calvo FA; Casadei R; Cilla S; Deodato F; Di Gioia G; Di Marco M; Fuccio L; Bertini F; Guido A; Herman JM; Macchia G; Maidment BW; Miller RC; Minni F; Passoni P; Valentini C; Re A; Regine WF; Reni M; Falconi M; Valentini V; Mattiucci GC
BMC Cancer; 2019 Jun; 19(1):569. PubMed ID: 31185957
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
[TBL] [Abstract][Full Text] [Related]
17. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
[TBL] [Abstract][Full Text] [Related]
18. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy for margin positive pancreatic cancer: A propensity score matched analysis.
Takahashi C; Shridhar R; Huston J; Meredith K
Pancreatology; 2022 Apr; 22(3):396-400. PubMed ID: 35304103
[TBL] [Abstract][Full Text] [Related]
20. The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases.
Altman AM; White MJ; Marmor S; Shukla D; Chang K; Lou E; LaRocca CJ; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Cancer Control; 2022; 29():10732748221109991. PubMed ID: 35839251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
